Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma Trial Results at ASCO Annual Meeting
Date:5/16/2008

e Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
2. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
3. Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting
4. Oncolytics Biotech Inc. Announces 2008 First Quarter Results
5. Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells
6. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
7. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting
8. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting
9. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial
10. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
11. Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... TORONTO , Aug. 18, 2014 /PRNewswire/ - SQI Diagnostics ... and commercializes proprietary technologies and products for advanced microarray ... call on Friday, August 22 at 2:00 pm ET.  ... , CEO, will provide a brief review of SQI,s ... Pronovost , a diagnostics industry veteran recently appointed to ...
(Date:8/18/2014)... , August 18, 2014 ... Transparency Market Research "Life Science Reagents Market(Products- PCR ... Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and Others; End ... Institutions, Clinical Laboratories, and Forensic Laboratories)- Global Industry ... - 2019", the global life science reagents market ...
(Date:8/18/2014)... , 18. August 2014 ... in eine internationale klinische Studie auf, in ... Die Linse soll das Sehvermögen bei allen ... der Operation möglicherweise keine Lese- oder Gleitsichtbrille ... dem Namen FluidVision Accommodating Intraocular Lens ...
(Date:8/15/2014)... FOREST, Ill. , Aug. 15, 2014   ... world,s leading provider of injectable drugs and infusion technologies, ... Morgan Stanley Global Healthcare Conference on Tuesday, Sept. 9, ... The presentation is scheduled to begin at 11:45 ... will be available to all interested parties through a ...
Breaking Biology Technology:SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... YORK, April 17 The market for congestive ... billion in 2007, and is,expected to reach $30 ... by,Kalorama Information, Congestive Heart Failure: Major World Markets, ... three factors: an,increased incidence of CHF, the application ...
... JENA, Germany, April 17 Occlutech GmbH, the leading,European ... a recent news release., In a news release ... opinion from AIPPI the European "Association for the Protection,of ... of,certain European IP held by AGA Medical., AIPPI ...
... April 17 BioMed Realty Trust, Inc.,(NYSE: BMR ... of 5,700,000,shares of common stock at $25.50 per share. ... 22, 2008. Gross proceeds from the offering will be,approximately ... of the,offering to repay a portion of the outstanding ...
Cached Biology Technology:Genomics Likely to Replace Traditional Drug Therapies in Treating CHF 2Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical 2BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock 2BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock 3
(Date:8/19/2014)... to encourage healthier spending habits? A new study by ... by tracking the purchasing records in a supermarket chain ... nutritional value of foods for sale. , The researchers, ... and Brian Wansink PhD, author of Slim by Design ... Supermarkets in the Northeastern United States between January 2005 ...
(Date:8/19/2014)... the world, leprosy and tuberculosis live side-by-side. Worldwide ... per year, with nearly all of them occurring ... vaccine Bacille Calmette-Guerin, or BCG, provides only partial ... more potent vaccine is needed to combat both ... weapon against both diseases., In a study published ...
(Date:8/19/2014)... (Boston) Some infants born with neonatal abstinence ... a more difficult time going through withdrawal than ... understood. While genetic and epigenetic (when genes are ... identified as potential factors, researchers at Boston University ... (BMC) conducted a first of its kind study ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2
... American scientists have rediscovered a highly distinctive mammal C a ... years ago. Furthermore, it has never before been discovered in ... extinct. , The greater dwarf cloud rat (Carpomys melanurus) has ... eyes, small rounded ears, a broad and blunt snout, and ...
... throughout the sciences in the study of biological, technological, ... to visualize or understand. In a May 1 ... links in networks, Santa Fe Institute (SFI) researchers Aaron ... real-world networks can be understood as a hierarchy of ...
... Iowa and HOUSTON, Texas The first year ... at Iowa State University (ISU) has supported 26 ... to further diversify Americas sources of energy and ... third-largest integrated energy company in the United States, ...
Cached Biology News:Dwarf cloud rat rediscovered after 112 years 2Dwarf cloud rat rediscovered after 112 years 3Nature paper describes technique for extracting hierarchical structure of networks 2Iowa State-ConocoPhillips collaboration advances 26 research projects in first year 2
Whole blood is collected from healthy pigs (mixed breed, either sex) at the time of slaughter, refrigerated within 6 hours, processed within 24 hours and frozen at -20ºC....
... Rhesus Serum • Rhesus serum is collected ... 5-7 years of age. Available Anticoagulants: ... Heparin (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
... DCTD_HUMAN GI Number: 4503277 ... Description: FUNCTION: Supplies the nucleotide ... dCMP + H 2 O = ... Homohexamer. SIMILARITY: Belongs to the Diseases: ...
Biology Products: